Presentations
Asarina Pharma CEO Peter Nordkild will present the company’s positive results from its Phase IIa study of Sepranolone for Tourette Syndrome at events in May and June 2023 in Europe and the US. See the schedule here.
May 19: Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah) presents Asarina Pharma’s Phase IIa results at TicCon – the Virtual National Conference of the Tourette Association of America, at 9.30 PM CET. His presentation is titled: ‘Putative novel pharmacological treatments for tic disorders’. Register here: https://touretteconference.org/en/registration
June 5-8: CEO and Business Development Officer Otto Skolling attend BIO 2023, Boston International Convention Center, Boston Mass. US. Register here: https://www.bio.org/events/bio-international-convention
June 7-9: CEO Peter Nordkild presents the full Phase IIa data at EESTS, the 15th European Conference on Tourette Syndrome and Tic Disorders in Brussels Belgium. Register for the event here: https://www.essts.org/registration
Follow us on our social media channels as we post on each event.
Tourette Syndrome
Watch our CEO Peter Nordkild explain the positive results of our Phase IIa study in Tourette Syndrome, at the RedEye Investor Forum in Gothenburg April 20, 2023 .
phase iia tourette syndrome results
Watch CEO Peter Nordkild discuss Asarina’s positive results with Direkt Studios, April 17, 2023 (interview begins 1 min 33 secs).
Explore our presentations Archive
REDEYE: Asarina Pharma: CEO Peter Nordkild presents at Investor Forum Online Feb 25th
direky stufoiesREDEYE: Asarina Pharma: Interview with CEO Peter Nordkild
REDEYE: Asarina Pharma: CEO Peter Norkild presents at Redeye Life Science Day 2020
REDEYE: Asarina Pharma: CEO Peter Nordkild presents at Neurology Seminar 2020
Press Kit
Access a range of resources on the Asarina Pharma team and offering.
The team
Management team
Scientific Advisory board